1. Bill Ackman Has Made Over $2.2 Billion On A Deal That's Arguably A Failure

    Bill Ackman Has Made Over $2.2 Billion On A Deal That's Arguably A Failure

    Irish pharmaceutical company Actavis buying Allergan for for $219 per share in a cash and stock deal  valued at $66 billion.  For months, Allergan has worked to fend off a hostile bid from Canadian pharmaceutical company Valeant and activist investor Bill Ackman. All of Ackman and Valeant's offers had been rejected. The most recent bid for the Botox-maker was  $53 billion. Even though Valeant ...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
  2. Topics Mentioned

  3. Authors